Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Article Oncology

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis

G. Curigliano et al.

Summary: In patients with HER2+ metastatic breast cancer, the combination of tucatinib, trastuzumab, and capecitabine provides a clinically significant improvement in overall survival and progression-free survival.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update

Naren Ramakrishna et al.

Summary: This article provides updated evidence-based guideline recommendations for the management of brain metastases in patients with HER2-positive advanced breast cancer up to 2021. The recommendations include appropriate local therapy and systemic therapy based on factors such as patient prognosis, symptoms, and metastasis characteristics.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

J. Cortes et al.

Summary: Among patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, trastuzumab deruxtecan was associated with a lower risk of disease progression or death compared to trastuzumab emtansine. However, treatment with trastuzumab deruxtecan was associated with interstitial lung disease and pneumonitis.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial

Rupert Bartsch et al.

Summary: The TUXEDO-1 trial demonstrates the efficacy of trastuzumab deruxtecan, an antibody-drug conjugate, in treating brain metastases in patients with HER2-positive breast cancer. The study showed a high intracranial response rate and maintained quality of life and cognitive functioning in the patients.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Shanu Modi et al.

Summary: Trastuzumab deruxtecan demonstrated significantly longer progression-free and overall survival compared to physician's choice chemotherapy in patients with HER2-low metastatic breast cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini et al.

Summary: Novel antibody-drug conjugates targeting HER2 have shown high activity in HER2-negative breast cancer with low HER2 expression, but the clinical and molecular characteristics of HER2-low breast cancer remain unclear. This study reveals that HER2-low is more common in HR-positive disease than in TNBC, and emphasizes the significant biological heterogeneity of HER2-low BC, highlighting the importance of reproducible and sensitive assays for measuring low HER2 expression.

NPJ BREAST CANCER (2021)

Add to Collection

Meeting Abstract Oncology

Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)

C. Saura Manich et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Obstetrics & Gynecology

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

Diana Lueftner et al.

Summary: Despite therapeutic gains in the treatment of HER2-positive advanced/metastatic breast cancer, there is still an urgent need for more effective treatment options. Trastuzumab deruxtecan (T-DXd) represents successful antibody engineering and has shown promising outcomes in clinical trials, providing a new treatment option for patients who have undergone intensive prior treatments.

GEBURTSHILFE UND FRAUENHEILKUNDE (2021)

Add to Collection

Article Medicine, General & Internal